Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 23:05 | 2026-08-11 | AMGN | AMGEN INC | Khosla Rachna | Officer | OPT+S | $414.05 | 3,252 | $1,346,499 | 6,404 |
| 2026-08-13 21:43 | 2026-08-13 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $0.92 | 1,900 | $1,748 | 375,785 |
| 2026-08-13 21:01 | 2026-08-11 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | Officer | SELL | $25.07 | 2,857 | $71,625 | 281,763 |
| 2026-08-13 20:10 | 2026-08-12 | XFOR | X4 Pharmaceuticals, Inc | Craig Adam R | Director, Officer | SELL | $4.44 | 47,436 | $210,829 | 328,651 |
| 2026-08-13 20:13 | 2026-08-12 | XFOR | X4 Pharmaceuticals, Inc | Volpone John | Officer | SELL | $4.44 | 24,576 | $109,228 | 265,305 |
| 2026-08-12 23:33 | 2026-08-10 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $25.00 | 3,000 | $75,000 | 396,989 |
| 2026-08-12 23:34 | 2026-08-10 | EXEL | EXELIXIS, INC. | Beckerle Mary C | Director | SELL | $53.66 | 9,812 | $526,512 | 16,079 |
| 2026-08-12 21:04 | 2026-08-10 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Officer | SELL | $12.97 | 7,632 | $98,987 | 99,425 |
| 2026-08-12 21:05 | 2026-08-10 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Officer | SELL | $12.97 | 11,447 | $148,468 | 224,215 |
| 2026-08-12 21:06 | 2026-08-10 | REPL | Replimune Group, Inc. | Hill Emily Luisa | Officer | SELL | $12.97 | 11,448 | $148,481 | 225,108 |
| 2026-08-12 21:07 | 2026-08-10 | REPL | Replimune Group, Inc. | Patel Sushil | Director, Officer | SELL | $12.97 | 39,341 | $510,253 | 708,151 |
| 2026-08-12 20:05 | 2026-08-10 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | OPT+S | $125.16 | 113,318 | $14,183,051 | 818,938 |
| 2026-08-11 21:43 | 2026-08-10 | HALO | HALOZYME THERAPEUTICS, INC. | Connaughton Bernadette | Director | SELL | $102.80 | 1,626 | $167,153 | 40,418 |
| 2026-08-11 20:05 | 2026-08-07 | TWST | Twist Bioscience Corp | CHESS ROBERT | Director | OPT+S | $110.89 | 18,417 | $2,042,261 | 21,084 |
| 2026-08-10 20:12 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. | 10% owner | BUY | $17.00 | 382,352 | $6,499,984 | 4,181,367 |
| 2026-08-07 20:15 | 2026-07-22 | OKYO | OKYO Pharma Ltd | Dempsey Robert John | Director, Officer | BUY | $1.54 | 15,000 | $23,085 | 15,000 |
| 2026-08-07 20:15 | 2026-07-27 | OKYO | OKYO Pharma Ltd | Patil Rajkumar V. | Officer | BUY | $1.49 | 3,363 | $5,011 | 20,030 |
| 2026-08-07 20:15 | 2026-07-21 | OKYO | OKYO Pharma Ltd | Mantelli Flavio | Officer | BUY | $1.40 | 20,000 | $28,000 | 20,000 |
| 2026-08-07 20:05 | 2026-08-05 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $109.75 | 14,205 | $1,558,999 | 89,866 |
| 2026-08-07 20:11 | 2026-08-05 | MRNA | Moderna, Inc. | Bancel Stephane | Director, Officer | OPT+S | $57.52 | 499,246 | $28,715,032 | 6,187,791 |
| 2026-08-07 20:15 | 2026-07-21 | OKYO | OKYO Pharma Ltd | BRANCACCIO JOHN P | Director | BUY | $1.48 | 5,000 | $7,385 | 35,201 |
| 2026-08-07 20:15 | 2026-07-21 | OKYO | OKYO Pharma Ltd | JACOB GARY S | Director, Officer | BUY | $1.40 | 3,500 | $4,900 | 112,420 |
| 2026-08-07 20:15 | 2026-07-20 | OKYO | OKYO Pharma Ltd | CERRONE GABRIELE M | Director, 10% owner | BUY | $1.40 | 25,000 | $35,000 | 10,851,416 |
| 2026-08-07 20:15 | 2026-07-21 | OKYO | OKYO Pharma Ltd | CERRONE GABRIELE M | Director, 10% owner | BUY | $1.45 | 22,500 | $32,625 | 10,873,916 |
| 2026-08-08 01:47 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Redmile Group, LLC | 10% owner | BUY | $17.00 | 600,000 | $10,200,000 | 1,182,854 |
| 2026-08-08 00:00 | 2026-08-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer | OPT+S | $134.17 | 5,500 | $737,935 | 168,498 |
| 2026-08-07 22:45 | 2026-08-06 | AMGN | AMGEN INC | Grygiel Nancy A. | Officer | OPT+S | $402.16 | 2,970 | $1,194,415 | 7,340 |
| 2026-08-07 22:47 | 2026-08-06 | AMGN | AMGEN INC | Miller Derek | Officer | OPT+S | $402.54 | 3,890 | $1,565,898 | 12,462 |
| 2026-08-07 19:45 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Sanofi | 10% owner | BUY | $17.00 | 300,000 | $5,100,000 | 1,082,855 |
| 2026-08-06 21:35 | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Frazier Life Sciences XI, L.P. | 10% owner | BUY | $17.00 | 588,235 | $9,999,995 | 6,154,213 |
| 2026-08-06 21:09 | 2026-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $3.25 | 30,000 | $97,500 | 6,188,287 |
| 2026-08-05 20:03 | 2026-08-03 | BIIB | BIOGEN INC. | Minor Lloyd | Director | SELL | $202.15 | 1,186 | $239,750 | 2,689 |
| 2026-08-05 20:05 | 2026-08-03 | VCEL | Vericel Corp | Halpin Michael | Officer | OPT+S | $46.84 | 10,000 | $468,400 | 16,394 |
| 2026-08-05 20:05 | 2026-08-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer | SELL | $85.32 | 2,888 | $246,408 | 269,678 |
| 2026-08-05 20:05 | 2026-08-03 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $85.32 | 1,133 | $96,669 | 119,281 |
| 2026-08-05 20:05 | 2026-08-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $85.32 | 5,101 | $435,223 | 818,938 |
| 2026-08-05 20:05 | 2026-08-03 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer | SELL | $85.32 | 167 | $14,249 | 46,160 |
| 2026-08-05 20:05 | 2026-08-03 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $85.32 | 1,070 | $91,294 | 104,071 |
| 2026-08-05 20:03 | 2026-08-04 | FATE | FATE THERAPEUTICS INC | TAHL CINDY | Officer | SELL | $2.46 | 38,800 | $95,405 | 589,355 |
| 2026-08-05 20:01 | 2026-08-04 | FATE | FATE THERAPEUTICS INC | Valamehr Bahram | Director, Officer | SELL | $2.46 | 43,947 | $108,101 | 591,815 |
| 2026-08-05 23:01 | 2026-08-05 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Officer | OPT+S | $55.00 | 17,000 | $935,068 | 76,756 |
| 2026-08-05 20:59 | 2026-08-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | OPT+S | $53.86 | 2,250 | $121,195 | 157,541 |
| 2026-08-05 20:58 | 2026-08-03 | PCVX | Vaxcyte, Inc. | GUGGENHIME ANDREW | Officer | OPT+S | $53.89 | 10,000 | $538,879 | 105,176 |
| 2026-08-05 20:07 | 2026-08-03 | EDIT | Editas Medicine, Inc. | Parison Amy | Officer | SELL | $2.58 | 678 | $1,749 | 14,292 |
| 2026-08-05 20:08 | 2026-08-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $1.98 | 275 | $544 | 504,819 |
| 2026-08-05 20:08 | 2026-08-03 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer | SELL | $26.73 | 34,501 | $922,315 | 255,263 |
| 2026-08-05 20:10 | 2026-08-04 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer | SELL | $10.23 | 26,842 | $274,596 | 844,895 |
| 2026-08-04 20:05 | 2026-08-03 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | SELL | $9.58 | 10,000 | $95,800 | 131,633 | |
| 2026-08-04 21:40 | 2026-08-03 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | SELL | $130.31 | 15,000 | $1,954,694 | 592,133 |
| 2026-08-04 20:45 | 2026-08-03 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer | SELL | $10.05 | 12,415 | $124,722 | 871,737 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.